A

    Arcadia Biosciences Inc (RKDA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

    $0.52
    -0.01 (-2.06%)

    Market Cap: $1.28M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -28.26%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.38N/AN/ABeat+88.3%
    Mar 26
    		$-2.11$-0.80-163.16%Miss-210.8%
    Dec 25
    		$-0.98$-0.09-984.33%Miss+67.4%
    Sep 25
    		$0.62$-0.54+214.81%Beat+171.3%
    Jun 25
    		$-3.26$-0.79-312.66%Miss-517.9%
    Mar 25
    		$1.90$-0.98+293.88%Beat+206.7%
    Dec 24
    		$-2.99$-0.89-235.96%Miss-18.7%
    Sep 24
    		$-0.87$-0.77-12.99%Miss+54.0%
    Jun 24
    		$0.78$1.55-49.68%Miss+27.9%
    Mar 24
    		$-1.78$-2.21+19.46%Beat+83.6%
    Dec 23
    		$-2.52$-2.58+2.33%Beat+59.9%
    Sep 23
    		$-1.89$-2.93+35.49%Beat+75.5%
    Jun 23
    		$0.61N/A+112.40%Beat+107.4%
    Mar 23
    		$-10.86$-6.60-64.55%Miss-24.3%
    Dec 22
    		$-6.29$-6.80+7.50%Beat+43.8%
    Sep 22
    		$-7.70$-7.60-1.32%Miss+37.7%
    Jun 22
    		$-8.28$-12.40+33.23%Beat+5.5%
    Mar 22
    		$-8.74$-12.40+29.52%Beat+26.3%
    Dec 21
    		$-11.20$-12.00+6.67%Beat-131.8%
    Sep 21
    		$-12.35$-9.60-28.65%Miss+51.6%
    Jun 21
    		$-8.76$-9.20+4.78%Beat+69.3%
    Mar 21
    		$-11.86$-12.20+2.79%Beat+54.0%
    Dec 20
    		$35.20$-16.40+314.63%Beat+276.0%
    Sep 20
    		$-25.52$-21.60-18.15%Miss+30.9%
    Jun 20
    		$-28.56$-24.20-18.02%Miss+31.2%
    Mar 20
    		$-25.80$-19.20-34.38%Miss+25.2%
    Dec 19
    		$-20.00$-23.00+13.04%Beat-257.1%
    Sep 19
    		$-36.93$-31.20-18.37%Miss-11.0%
    Jun 19
    		$-41.50$-37.60-10.37%Miss+48.6%
    Mar 19
    		$-34.48$-40.40+14.65%Beat+82.3%
    Dec 18
    		$-5.60N/A+81.58%Beat-302.9%
    Sep 18
    		$-33.26$-45.20+26.42%Beat+51.0%
    Jun 18
    		$-80.80$-51.60-56.59%Miss-12.2%
    Mar 18
    		$-194.40$-56.00-247.14%Miss-143.0%
    Dec 17
    		$-1.39$-2.00+30.50%Beat+98.7%
    Sep 17
    		$-67.92$-64.00-6.13%Miss+5.7%
    Jun 17
    		$-72.00$-88.00+18.18%Beat-
    Mar 17
    		$-80.00$-56.00-42.86%Miss-
    Dec 16
    		$-104.00$-80.00-30.00%Miss-
    Sep 16
    		$-72.00$-56.00-28.57%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.18EV/EBITDA0.62x
    Price/FCF-0.61xFCF Yield-163.25%
    Profitability
    Profit Margin-234.50%Operating Margin-34.40%
    ROE-430.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-0.09x
    Current Ratio3.49xQuick Ratio2.92x
    Trading Statistics
    Beta0.55Avg Volume245.18K
    52-Week High$5.7252-Week Low$0.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.48
    SMA 20$0.56
    SMA 50$0.63
    SMA 200$1.64
    EMA 10$0.52
    EMA 20$0.55
    EMA 50$0.66
    EMA 200$1.54

    MACD

    Line: -0.05Signal: -0.05Hist: 0.00

    ADX

    ADX: 24.3+DI: 20.4-DI: 25.3

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down64.0
    PSAR$0.58

    Bollinger Bands

    Upper Band$0.77
    Lower Band$0.36
    %B Position7138%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    43.0

    Momentum Oscillators

    Stoch %K37.6
    Stoch %D36.1
    Williams %R-62.8
    ROC (10d)8.1%
    Momentum0.04
    CCI (20d)-36.9
    MFI (14d)64.2

    Volatility Measures

    ATR (14d)$0.07(12.6%)
    StdDev (20d)0.10
    Hist Vol135.2%(High)

    Volume Flow

    VWAP$0.51
    OBV208.4M
    AD Line-125.3M
    CMF (20d)-0.207

    Volume Metrics

    Avg Vol (20d)256.4K
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.59

    Pivot Points

    R3$0.60
    R2$0.58
    R1$0.55
    Pivot Point$0.53
    S1$0.50
    S2$0.48
    S3$0.45

    Advanced Oscillators

    TSI-20.35
    Ultimate Osc62.8
    KST-245.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.44M$1.10M$901,000$1.30M$1.46M$1.20M$1.22M$1.54M$1.31M$987,000$627,000$1.30M
    Cost of Revenue$812,000$700,000$708,000$884,000$824,000$682,000$827,000$1.03M$633,000$471,000$18,000$818,000
    Gross Profit$631,000$400,000$193,000$418,000$631,000$518,000$388,000$505,000$673,000$516,000$609,000$480,000
    Operating Expenses$1.13M$1.18M$1.57M$1.57M$1.13M$-12,000$2.67M$2.27M$-1,307,000$2.10M$-7,000$1.88M
    R&D$0$0$0$0$9,000$0$13,000$24,000$10,000$6,000$-337,000$15,000
    SG&A$1.13M$1.18M$1.57M$1.57M$2.12M$1.74M$2.65M$2.24M$2.68M$2.06M$227,000$1.86M
    Operating Income$-496,000$-779,000$-1,377,000$-1,152,000$-501,000$530,000$-2,280,000$-1,760,000$1.98M$-1,588,000$616,000$-1,397,000
    Interest Income$-5,423,000$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-2,000$-5,000$2,000$-7,000$-9,000$-207,000$-354,000$-233,000$-150,000$-45,000$-157,000$-133,000
    Income Before Tax$-2,834,000$-2,881,000$-3,305,000$-585,000$31,000$2.60M$-3,862,000$-1,197,000$1.70M$-950,000$1.36M$-639,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,266,000$-4,385,000$-1,336,000$856,000$-4,458,000$2.60M$-4,064,000$-1,612,000$1.06M$-2,423,000$-2,853,000$-2,567,000
    EBITDA$2.59M$-2,878,000$-3,301,000$-585,000$50,000$2.44M$-4,112,000$-1,334,000$1.73M$-767,000$7.51M$-505,000
    EBIT$2.59M$-2,886,000$-3,303,000$-592,000$22,000$2.39M$-4,216,000$-1,430,000$1.55M$-995,000$7.28M$-772,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RKDA

    News

    Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

    Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.

    Stock Titan•8/14/26•
    Neutral

    Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Arcadia Biosciences (RKDA) announced its second quarter and first half 2026 financial results, highlighting a significant reduction in cash used in operating activities and a strong cash balance. The company reported flat sales for Q2 2026 due to inventory and shipping issues, which have since been resolved, leading to a surge in July Zola sales. Arcadia plans to launch new Zola products in Q4 2026 and Q1 2027 to drive further growth, supported by a recent $4 million private placement.

    GlobeNewswire•8/14/26•
    Neutral

    Form 8K Arcadia Biosciences Inc For: 13 August By Investing.com

    This article reports on the filing of a Form 8K by Arcadia Biosciences Inc. on August 13. The company's stock symbol is RKDA, and its shares experienced a 9.60% increase. The brief announcement provides no further details about the content of the 8K filing.

    Investing.com Nigeria•8/13/26•
    Neutral

    Arcadia Biosciences, Inc. SEC Filing (Aug 10, 2026)

    This article reports on an SEC filing by Arcadia Biosciences, Inc. (RKDA) on August 10, 2026. The filing is an ARS type and its impact is assessed as low with a neutral sentiment. The document is available as a PDF and further details about RKDA's stock overview, rankings, and recent news and SEC filings are also provided.

    Stock Titan•8/10/26•
    Neutral

    Arcadia Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    Arcadia Biosciences (RKDA) received a Nasdaq notice on August 4, 2026, indicating non-compliance with the $1.00 minimum bid price rule. The company's stock has traded below this threshold for 30 consecutive business days. Arcadia Biosciences has 180 days, until February 1, 2027, to regain compliance, with a possibility of an extension.

    TradingView•8/10/26•
    Bearish

    Frequently Asked Questions About RKDA

    Does RKDA pay dividends?
    Arcadia Biosciences Inc (RKDA) does not currently pay a regular dividend.
    What is RKDA's market cap?
    Arcadia Biosciences Inc (RKDA) has a market capitalization of $1.28M with a current stock price of $0.52.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In